ABVC BioPharma, Inc.
ABVC
$1.23
-$0.08-6.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 20.91% | 36.53% | 189.52% | 68.35% |
| Total Other Revenue | -- | 91.77% | 98.29% | 98.29% | 98.29% |
| Total Revenue | -100.00% | 56.53% | 186.88% | 1,901.57% | 234.16% |
| Cost of Revenue | -- | -100.00% | -99.82% | -99.79% | -99.74% |
| Gross Profit | -100.00% | 115.73% | 1,292.07% | 334.43% | 440.17% |
| SG&A Expenses | 39.63% | 18.70% | -29.21% | -56.19% | -9.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -110.84% | 633.90% | 447.92% | 447.92% | 447.92% |
| Total Operating Expenses | 35.65% | 13.41% | -31.83% | -59.64% | -23.98% |
| Operating Income | -50.18% | -8.54% | 36.51% | 66.11% | 29.78% |
| Income Before Tax | -55.56% | -4.68% | 43.15% | 62.61% | 33.09% |
| Income Tax Expenses | 121.81% | -62.81% | -62.15% | -143.16% | -143.16% |
| Earnings from Continuing Operations | -59.29% | -3.84% | 43.30% | 64.82% | 36.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 31.46% | -53.33% | -40.73% | -28.84% | -27.70% |
| Net Income | -61.30% | -11.47% | 43.49% | 66.92% | 37.05% |
| EBIT | -50.18% | -8.54% | 36.51% | 66.11% | 29.78% |
| EBITDA | -50.67% | -8.58% | 36.70% | 66.49% | 29.96% |
| EPS Basic | 16.84% | 36.33% | 78.13% | 87.75% | 78.14% |
| Normalized Basic EPS | 26.72% | 21.73% | 78.08% | 87.85% | 77.40% |
| EPS Diluted | 16.75% | 35.86% | 77.94% | 87.61% | 78.03% |
| Normalized Diluted EPS | 26.72% | 21.73% | 78.08% | 87.85% | 77.40% |
| Average Basic Shares Outstanding | 72.17% | 71.44% | 82.34% | 118.28% | 169.00% |
| Average Diluted Shares Outstanding | 72.17% | 71.44% | 82.34% | 118.28% | 169.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |